Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.
25 April 2025
25 April 2025
Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.